Health Affairs, 28, no. 3 (2009): 723 doi: 10.1377/hlthaff.28.3.723 © 2009 by Project HOPE	New Online   House Health Reform Bill   Paying for Reform   Vetting AHIP's Report   HIV/AIDS Costs   Brief: Insurance Reform   HA Blog Top 10

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Related Collections Mental Health/Substance Abuse Pharmaceuticals Related Articles

Pharmaceuticals

PROLOGUE

Pharmaceuticals & Psychotropic Drugs

The invention of new pharmaceutical products has resulted in tremendous benefits for patients with mental health conditions. Antidepressants, for example, have relieved symptoms for millions for whom treatment was previously unavailable or ineffective. But greater reliance on pharmaceutical treatments has increased the vulnerability of those with mental illnesses to changes in the policies of public or private payers. Increased spending has prompted insurers, regulators, and public programs to experiment with coverage policies, formularies, patent law, and payment strategies—and sometimes has led pharmaceutical manufacturers to take actions that are not always in the public’s interest. Patients’ well-being is at stake at . . . [Full Text of this Article]

                      What's this?

Related Articles

• Susan H. Busch and Colleen L. Barry
  Pediatric Antidepressant Use After The Black-Box Warning
  Health Affairs, May/June 2009; 28(3): 724-733.
  [Abstract] [Full Text] [PDF]
   
  
• Haiden A. Huskamp, Alisa B. Busch, Marisa E. Domino, and Sharon-Lise T. Normand
  Antidepressant Reformulations: Who Uses Them, And What Are The Benefits?
  Health Affairs, May/June 2009; 28(3): 734-745.
  [Abstract] [Full Text] [PDF] [Appendix]
   
  
• Julie M. Donohue, Haiden A. Huskamp, and Samuel H. Zuvekas
  Dual Eligibles With Mental Disorders And Medicare Part D: How Are They Faring?
  Health Affairs, May/June 2009; 28(3): 746-759.
  [Abstract] [Full Text] [Figures Only] [PDF]